The treatment and management of respiratory disease continue to rapidly advance. In the past five years alone, we have seen the introduction of new and generic inhaled fixed dose combination products in asthma and COPD, new biologic options in asthma, the first disease-specific products in IPF and novel modes of action in PAH. Differences in dosing frequency and delivery devices add to the options now available to physicians and their patients. In an increasingly crowded market, new entrants find themselves competing with established standards of care. At the same time, new clinical data challenges the current recommended treatment approaches and continues to divide physician opinion.
Endotyping according to specific biomarkers has seen biologic therapy taking hold in severe asthma and trials are also being conducted in COPD, IPF and Nasal Polyps as pharma-companies seek to extend their indications. This true personalization of medicine will only continue to become more precise as new biomarkers are discovered and understood.
The Respiratory set of Disease Specific Programmes™ are designed to capture the impact of these changes in terms of mapping the treatment landscape, understanding changing physician opinion and alignment with guidelines, and identifying areas of continued unmet need. Importantly, they continue to provide evidence to support the medical community in understanding respiratory disease in real-world populations. To date, Respiratory DSP data has yielded over 100 publications and is referenced in the preface of the 2017 GOLD Strategy document.